Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Current Assets (2017 - 2025)

Fennec Pharmaceuticals' Current Assets history spans 9 years, with the latest figure at $67.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 51.94% year-over-year to $67.0 million, compared with a TTM value of $67.0 million through Dec 2025, up 51.94%, and an annual FY2025 reading of $67.0 million, up 51.94% over the prior year.
  • Current Assets for Q4 2025 was $67.0 million at Fennec Pharmaceuticals, up from $46.1 million in the prior quarter.
  • The five-year high for Current Assets was $68.2 million in Q1 2024, with the low at $15.6 million in Q2 2022.
  • Average Current Assets over 5 years is $36.3 million, with a median of $28.1 million recorded in 2021.
  • Year-over-year, Current Assets crashed 44.6% in 2022 and then soared 221.62% in 2024.
  • Tracing FENC's Current Assets over 5 years: stood at $26.0 million in 2021, then grew by 2.88% to $26.7 million in 2022, then grew by 0.49% to $26.9 million in 2023, then skyrocketed by 64.29% to $44.1 million in 2024, then surged by 51.94% to $67.0 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Current Assets are $67.0 million (Q4 2025), $46.1 million (Q3 2025), and $40.8 million (Q2 2025).